Evidence map›Paper›PMID 33667669›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.

D M Barrios, G S Phillips, A N Geisler, S R Trelles, A Markova, S J Noor, E A Quigley, H C Haliasos, A P Moy, A M Schram and 12 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Review
  6. AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Review
  7. Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review.JID innovations : skin science from molecules to population health · 2025
    Article
  8. Review
  9. Article
  10. Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

D M BarriosDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
G S PhillipsDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
A N GeislerDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
S R TrellesDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
A MarkovaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
S J NoorDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
E A QuigleyDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
H C HaliasosDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA.
A P MoyDepartment of Dermatology, Weill Cornell Medicine, New York, USA; Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
A M SchramDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
J BrombergDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
S A FuntDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
M H VossDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
A DrilonDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
M D HellmannDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
E A ComenDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medicine, New York, USA.
S NaralaDepartment of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
A B PatelDepartment of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
M WetzelDivision of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, USA.
J Y JungDivision of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, USA; Dermatology Service, Department of Medical Oncology, Norton Cancer Institute, Louisville, USA.
D Y M LeungDepartment of Pediatrics, National Jewish Health, Denver, USA.
M E LacoutureDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Dermatology, Weill Cornell Medicine, New York, USA. Electronic address: LacoutuM@mskcc.org.
Cornell University · USMemorial Sloan Kettering Cancer Center · USWeill Cornell Medicine · USThe University of Texas MD Anderson Cancer Center · USNational Jewish Health · USNorton Healthcare · USUniversity of Louisville · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy U01AR077511 · NIAMS · NATIONAL JEWISH HEALTH · PI KERN, JEFFREY A, LACOUTURE, MARIO · 2020 to 2024
$3.1M
NCI NIH HHS P30 CA008748NIAMS NIH HHS U01 AR077511
6 · The paper itself

Abstract

backgroundImmunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous pemphigoid, urticaria). In oncology, pruritus-associated cutaneous adverse events (paCAEs) are frequent with immune checkpoint inhibitors (CPIs) and targeted anti-human epidermal growth factor receptor 2 (HER2) therapies. Thus, we sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory paCAEs related to CPIs and anti-HER2 agents. PATIENTS AND

methodsPatients included in this multicenter retrospective analysis received monthly subcutaneous injections of omalizumab for CPI or anti-HER2 therapy-related grade 2/3 pruritus that was refractory to topical corticosteroids plus at least one additional systemic intervention. To assess clinical response to omalizumab, we used the Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint was defined as reduction in the severity of paCAEs to grade 1/0.

resultsA total of 34 patients (50% female, median age 67.5 years) received omalizumab for cancer therapy-related paCAEs (71% CPIs; 29% anti-HER2). All had solid tumors (29% breast, 29% genitourinary, 15% lung, 26% other), and most (n = 18, 64%) presented with an urticarial phenotype. In total 28 of 34 (82%) patients responded to omalizumab. The proportion of patients receiving oral corticosteroids as supportive treatment for management of paCAEs decreased with IgE blockade, from 50% to 9% (P < 0.001). Ten of 32 (31%) patients had interruption of oncologic therapy due to skin toxicity; four of six (67%) were successfully rechallenged following omalizumab. There were no reports of anaphylaxis or hypersensitivity reactions related to omalizumab.

conclusionsIgE blockade with omalizumab demonstrated clinical efficacy and was well tolerated in cancer patients with pruritus related to CPIs and anti-HER2 therapies.

Indexed as

Immunoglobulin EOmalizumabAgedFemaleHumansImmune Checkpoint InhibitorsMalePruritusRetrospective StudiesImmune Checkpoint InhibitorsImmunoglobulin EOmalizumabbullous pemphigoidcutaneous adverse eventeczemaIgEpruritusurticaria

Identifiers

PMID33667669
PMCPMC9282165
OpenAlexW3134398642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.